Emeis Stock Consolidates After Targeting 17 Euros

TP Icap Midcap Targets 17 Euros, a 19% Potential Upside

On April 28, 2026, TP Icap Midcap initiated a buy recommendation on Emeis, setting a target price at 17.00 euros. Compared to the current price of 14.28 euros, this target offers a potential appreciation of about 19%. This stance comes in a fundamentally revised context: the board announced on April 24 the appointment of Jean-Marc Boursier as Deputy CEO effective from July 1, 2026, while he continues to serve as the group's CFO. Operationally, the annual results published at the beginning of April showed a 19.2% increase in comparable EBITDAR for the fiscal year 2025, despite a residual net loss of 298 million euros. The refinancing of 3.15 billion euros and asset disposals have also helped lighten the group's financial structure following its exit from the safeguard plan.

Consolidation After Contact with the Upper Bollinger Band

Technically, today's decline follows the stock touching the upper Bollinger band at 14.92 euros the previous day. The price is now in the upper 75% of the channel, a configuration that may indicate a pause phase after several bullish sessions. The RSI, at 55, remains in neutral territory and does not send any extreme signals. Above, the technical resistance identified at 15.06 euros is the next threshold to watch to validate the continuation of the movement that began in early April, with the stock maintaining a gain of nearly 30% over the year and 4% over the past week. In the short term, the 50-day moving average at 14.00 euros provides a first technical support point, while the main support is at 12.26 euros. Among comparable sector values, Clariane is down 1.13% in the session while Ramsay Générale de Santé is up 0.41%. The next concrete appointment for shareholders will be the publication of the first quarter 2026 revenue, scheduled for May 6.